Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Study reveals how inflammation triggers colon cancer cells to metastasize

Study reveals how inflammation triggers colon cancer cells to metastasize

A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois, M.D., Ph.D., has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize. [More]
Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and poor survival. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery. [More]
Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer. [More]
Study sheds light on fertility concerns of young breast cancer patients

Study sheds light on fertility concerns of young breast cancer patients

Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back. [More]
FSU investigator solves cell division mystery

FSU investigator solves cell division mystery

In the second part of his lab's recent one-two punch, Florida State University researcher Daniel Kaplan said he has solved a cell division mystery in a way that will intrigue the makers of cancer-fighting drugs. [More]
Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. [More]
UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas. [More]
Women diagnosed with ductal carcinoma in situ more likely to die from breast cancer

Women diagnosed with ductal carcinoma in situ more likely to die from breast cancer

Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general U.S. population, according to a new study led by Dr. Steven Narod. [More]
UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern, NASA to study zero-gravity effects on the human brain in cancer patients

UT Southwestern Medical Center researchers, in conjunction with NASA, will take four volunteer cancer patients on a zero-gravity ride into the upper atmosphere to study why zero-gravity conditions on the International Space Station sometimes affect the vision of astronauts staying there for extended periods. [More]
PHD1 inhibition may have therapeutic potential for colorectal cancer

PHD1 inhibition may have therapeutic potential for colorectal cancer

Scientists at VIB and KU Leuven have shown that blocking the PHD1 oxygen sensor hinders the activation of p53, a transcription factor that aids colorectal cancer (CRC) cells in repairing themselves and thus resisting chemotherapy. Chemotherapy resistance remains a major clinical issue in the treatment of CRC. These findings indicate that PHD1 inhibition may have valuable therapeutic potential. The study was published in the leading medical journal EMBO Molecular Medicine, which features molecular biology-driven research. [More]
New partnering scholarship launched to inspire and develop potential oncology nurses

New partnering scholarship launched to inspire and develop potential oncology nurses

As experienced oncology nurses know, a cancer diagnosis is only the first step on a long and challenging road ahead—for patients and providers alike. For both, a wide range of procedures becomes part and parcel of every day. [More]
EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. [More]
First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma. [More]
MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

A study from Massachusetts General Hospital Cancer Center researchers - the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients - reveals not only specific structural changes within patients' brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased. [More]
Peripherally inserted central catheter use associated with lower-extremity DVT

Peripherally inserted central catheter use associated with lower-extremity DVT

Peripherally inserted central catheters (PICCs), a type of IV typically inserted in a vein in the arm, are frequently used by healthcare professionals to obtain long-term central venous access in hospitalized patients. While there are numerous benefits associated with PICCs, a potential complication is deep vein thrombosis (DVT), or blood clots, in upper limbs. [More]
DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project. [More]
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). [More]
New system accurately and reliably captures patient experience with cancer drug side effects

New system accurately and reliably captures patient experience with cancer drug side effects

In cancer clinical trials, symptom side effects patients experience, like nausea, are typically reported by doctors, and not directly by patients. Previous research has shown that doctors under-report these symptoms. [More]
Advertisement
Advertisement